18002-26-1

Usage

Uses

Used in Pharmaceutical Research and Development:
1-(tetrahydrofuran-2-yl)pyrimidine-2,4(1H,3H)-dione is used as a chemical compound for its potential as an anticancer agent, inhibiting the growth of certain cancer cells.
Used in Cancer Treatment:
1-(tetrahydrofuran-2-yl)pyrimidine-2,4(1H,3H)-dione is used as a potential anticancer agent for its ability to inhibit the growth of certain cancer cells.
Used in Neurodegenerative Disease Treatment:
1-(tetrahydrofuran-2-yl)pyrimidine-2,4(1H,3H)-dione is used as a potential treatment for neurodegenerative diseases due to its pharmacological properties.
Used in Antiviral Therapy:
1-(tetrahydrofuran-2-yl)pyrimidine-2,4(1H,3H)-dione is used as a potential antiviral agent, with ongoing research to explore its full range of pharmacological properties and potential uses.

Upstream product

• 1608-67-9 2-acetoxytetrahydrofuran 
• 66-22-8 uracil 
• 10457-14-4 O,O'-bis-(trimethylsilyl)uracil 
• 67095-56-1 1,3-bis-tetrahydrofuran-2-yl-1H-pyrimidine-2,4-dione 

Downstream Products

• 890524-70-6 3-(3,5-dimethyl-benzyl)-1-(tetrahydro-furan-2-yl)-1H-pyrimidine-2,4-dione 
• 17902-23-7 tegafur 
• 887246-99-3 3-(2-diethoxyphosphinylbenzyl)-1-(tetrahydrofuran-2-yl)pyrimidine-2,4-dione 

Relevant academic research and scientific papers

Structure-activity relationship studies on N3-substituted willardiine derivatives acting as AMPA or kainate receptor antagonists

N3-Substitution of the uracil ring of willardiine with a variety of carboxyalkyl or carboxybenzyl substituents produces AMPA and kainate receptor antagonists. In an attempt to improve the potency and selectivity of these AMPA and kainate receptor antagonists a series of analogues with different terminal acidic groups and interacidic group spacers was synthesized and pharmacologically characterized. (5′)-1-(2-Amino-2-carboxyethyl)-3-(2- carboxythiophene-3-ylmethyl)pyrimidine-2,4-dione (43, UBP304) demonstrated high potency and selectivity toward native GLUK5-containing kainate receptors (KD 0.105 ± 0.007 μM vs kainate on native GLUK5; KD 71.4 ± 8.3 μM vs (S)-5- fluorowillardiine on native AMPA receptors). On recombinant human GLU K5, GLUK5/GLUK6, and GLUK5/GLU K2, KB values of 0.12 ± 0.03, 0.12 ± 0.01, and 0.18 ± 0.02 μM, respectively, were obtained for 43. However, 43 displayed no activity on homomeric GLUK6 or GLUK7 kainate receptors or homomeric GLUA1-4 AMPA receptors (IC50 values > 100 μM). Thus, 43 is a potent and selective GLUK5 receptor antagonist.

Synthesis of tetrahydro-2-furylated pyrimidine derivatives

The synthesis of 1-(tetrahydro-2-furyl) pyrimidine derivatives in good yields by the reaction of trimethylsilylated pyrimidine bases with 2-acetoxytetrahydrofuran using a catalytic amount of cesium chloride in acetonitrile under mild conditions is described.

FACILE SYNTHESIS OF TETRAHYDRO-2-FURYLATED PYRIMIDINES AND PURINES USING A NEW CATALYST OF CESIUM CHLORIDE

1-(Tetrahydro-2-furyl)pyrimidine and 9-(tetrahydro-2-furyl)purine derivatives were successfully synthesized in good yields by the reactions of trimethylsilylated pyrimidine and purine bases with 2-acetoxytetrahydrofuran using a new catalyst of cesium chloride in acetonitrile under mild conditions.